CN115811981A - 包含胎儿附属物来源组织细胞培养上清的脑神经损伤治疗剂 - Google Patents

包含胎儿附属物来源组织细胞培养上清的脑神经损伤治疗剂 Download PDF

Info

Publication number
CN115811981A
CN115811981A CN202180047221.2A CN202180047221A CN115811981A CN 115811981 A CN115811981 A CN 115811981A CN 202180047221 A CN202180047221 A CN 202180047221A CN 115811981 A CN115811981 A CN 115811981A
Authority
CN
China
Prior art keywords
cranial nerve
cells
agent
derived
culture supernatant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180047221.2A
Other languages
English (en)
Chinese (zh)
Inventor
相良祐辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kochi University NUC
Original Assignee
Kochi University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kochi University NUC filed Critical Kochi University NUC
Publication of CN115811981A publication Critical patent/CN115811981A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202180047221.2A 2020-06-30 2021-06-30 包含胎儿附属物来源组织细胞培养上清的脑神经损伤治疗剂 Pending CN115811981A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020113456 2020-06-30
JP2020-113456 2020-06-30
JP2020-149878 2020-09-07
JP2020149878A JP6967308B1 (ja) 2020-06-30 2020-09-07 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
PCT/JP2021/024837 WO2022004816A1 (ja) 2020-06-30 2021-06-30 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Publications (1)

Publication Number Publication Date
CN115811981A true CN115811981A (zh) 2023-03-17

Family

ID=78509585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180047221.2A Pending CN115811981A (zh) 2020-06-30 2021-06-30 包含胎儿附属物来源组织细胞培养上清的脑神经损伤治疗剂

Country Status (5)

Country Link
US (1) US20230242870A1 (https=)
EP (1) EP4173629A4 (https=)
JP (2) JP6967308B1 (https=)
CN (1) CN115811981A (https=)
WO (1) WO2022004816A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
CN117679520A (zh) * 2022-09-09 2024-03-12 北京达尔文细胞生物科技有限公司 用于防治后遗症期面神经麻痹的药物组合物及其应用
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法
WO2025182103A1 (ja) * 2024-02-28 2025-09-04 セルソース株式会社 脳梗塞の機能予後改善用組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098361A2 (en) * 2001-06-01 2002-12-12 Xcyte Therapies, Inc. T cell induced tissue repair and regeneration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
WO2005001080A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2006071778A2 (en) * 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
EP2139497B1 (en) * 2007-04-13 2013-11-06 Stemnion, INC. Methods for treating nervous system injury and disease
JP6095893B2 (ja) * 2008-12-19 2017-03-15 デピュイ・シンセス・プロダクツ・インコーポレイテッド 傷害後の神経組織の再生および修復
SG174551A1 (en) * 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
MX2013006592A (es) * 2010-12-17 2014-02-06 Anthrogenesis Corp Tratamiento de lesion de la medula espinal y lesion traumatica de cerebro empleando celulas adherentes obtenidas del amnios.
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
CN104321426A (zh) * 2012-03-28 2015-01-28 石匠株式会社 永生化干细胞以及以其生成物为有效成分的药物组合物和药物制剂
US10167448B2 (en) * 2013-12-12 2019-01-01 Samsung Life Public Welfare Foundation Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
DK3145493T3 (da) * 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
EP3307286B1 (en) * 2015-06-12 2023-01-11 Hudson Institute of Medical Research Allogeneic mammalian amniotic exosomes for treating a fibrotic disease
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
KR20190109389A (ko) * 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
CA3064064A1 (en) * 2017-05-16 2018-11-22 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
CA3069805A1 (en) * 2017-07-14 2019-01-17 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
JP2020093988A (ja) * 2018-12-11 2020-06-18 株式会社 バイオミメティクスシンパシーズ 腸溶性カプセル
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098361A2 (en) * 2001-06-01 2002-12-12 Xcyte Therapies, Inc. T cell induced tissue repair and regeneration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONYA NAZARINIA等: "Conditioned medium obtained from human amniotic mesenchymal stem cells attenuates focal cerebral ischemia/reperfusion injury in rats by targeting mTOR pathway", JOURNAL OF CHEMICAL NEUROANATOMY, vol. 102, 6 January 2019 (2019-01-06), pages 2 *
李洪秋;崔丹;阿良;赵忠海;陈宾;: "人胎盘间充质干细胞移植对大鼠脊髓损伤区bFGF表达的影响", 辽宁医学院学报, no. 02, 15 April 2010 (2010-04-15) *

Also Published As

Publication number Publication date
JP2022016722A (ja) 2022-01-24
US20230242870A1 (en) 2023-08-03
EP4173629A4 (en) 2024-08-21
EP4173629A1 (en) 2023-05-03
JPWO2022004816A1 (https=) 2022-01-06
JP6967308B1 (ja) 2021-11-17
WO2022004816A1 (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
CN115811981A (zh) 包含胎儿附属物来源组织细胞培养上清的脑神经损伤治疗剂
US8475788B2 (en) Methods of treating spinal cord injury and minimizing scarring
US8263400B2 (en) Method for expanding adult stem cells from blood and compositions and methods for using the same
US9688733B2 (en) Method for treating spinal cord injury using HMGB1 fragment
WO2009008928A2 (en) Methods for treating nervous system injury and disease
CN101835891A (zh) 运用体外培养增殖的自我更新型集落形成细胞治疗疾病和功能紊乱症
KR20100065338A (ko) 인간 또는 동물 배아에서 중간엽 줄기세포를 추출 및 그 분비물을 추출하는 방법
US20170258843A1 (en) Stem cell mediated neuroregeneration and neuroprotection
CN108588026A (zh) 高表达il10的临床级间充质干细胞的制备方法及其用途
CN113549596B (zh) 一种诱导培养基及其使用方法和应用
JPWO2006041088A1 (ja) 脳移行性骨髄前駆細胞
CN115125192B (zh) 一种骨髓上清液及其在细胞培养中的应用
CN106701668A (zh) 间质干细胞、其纯株化扩张的方法、其分离方法及其应用
CN120574767A (zh) 人胎盘源促血管干细胞hPASCs及其应用
CN117919400B (zh) iPS诱导定向分化的成内皮祖细胞和抗体联合治疗心脑血管疾病
CN115996708A (zh) 含有脐带血单个核细胞培养上清的脑神经损伤治疗剂
RU2762855C1 (ru) Генно-клеточный везикулярный терапевтический препарат и способ терапии рассеянного склероза посредством трансплантации генно-клеточного везикулярного терапевтического препарата
Ma et al. SA/Col/SDF-1 neural scaffold promotes the homing of BMSCs and functional recovery in a rat model of traumatic brain injury
WO2007145889A1 (en) Methods of treating spinal cord injury and minimizing scarring
KR20130039467A (ko) 태반의 양막 유래 간엽줄기세포로부터 신경세포 및 유모세포를 분화시키는 방법
WO2022004822A1 (ja) 胎児付属物由来組織細胞及び／又は臍帯血細胞を培養するための海洋深層水を含む培地
HK1213201B (en) Novel method for treating spinal cord injury using hmgb1 fragment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230317